1268714-50-6

1268714-50-6 structure
1268714-50-6 structure
  • Name: Carotuximab
  • Chemical Name: Carotuximab
  • CAS Number: 1268714-50-6
  • Molecular Formula:
  • Molecular Weight:
  • Catalog: Signaling Pathways Stem Cell/Wnt TGF-beta/Smad
  • Create Date: 2023-02-23 21:26:45
  • Modify Date: 2024-01-14 00:56:14
  • Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2].

Name Carotuximab
Description Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2].
Related Catalog
In Vitro Carotuximab (TRC105;300 μg/mL;预处理 1 小时,然后共培养 12 小时) 降低人主动脉内皮细胞中 7-酮胆固醇诱导的内皮糖蛋白 (Eng) 蛋白水平和 pSmad1/5 和 pSmad2/3 信号通路。Carotuximab 介导的 Eng 阻断阻止了 7-酮胆固醇诱导的单核细胞通过内皮单层细胞的粘附和迁移[1]。 Western Blot Analysis[1] Cell Line: Human aortic endothelial cells (HAoECs) Concentration: 300 μg/mL Incubation Time: Pretreatment 1 h, and then co-cultured for 12 h Result: Reduced the 7-Ketocholesterol-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling.
In Vivo Carotuximab(TRC105;2 mg/kg;i.v;每 3 天一次;持续 8 周)与 Decitabine 一起在急性髓性白血病 (AML) 异种移植物中产生更持久的抗白血病作用,并且还能增强活性氧 (ROS) 活性[2]。 Animal Model: Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; 7-8 weeks) injected with primary AML-0032 cells[2] Dosage: 2 mg/kg Administration: i.v; every 3 days; for 8 weeks Result: Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts.
References

[1]. Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918.  

[2]. June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242.  

No Any Chemical & Physical Properties